BRANFORD, Conn., Oct. 16, 2012 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED) announced today the presentation of five clinical studies utilizing FORE-SIGHT® Absolute Tissue Oximetry at the annual meeting of the American Society of Anesthesiologists (ASA) underway in Washington, D.C. at the Walter E. Washington Convention Center through October 17th. An estimated 4,000 anesthesiologists from around the world are expected to attend this conference.
"There are now more than 200 papers, scientific posters and clinical study abstract publications related to the use of FORE-SIGHT Tissue Oximetry, and we are delighted that five presentations featuring our technology are being presented at the important ASA conference," said Thomas M. Patton, President and CEO of CASMED. "The data continue to accumulate showing that FORE-SIGHT Oximetry can be used to empower clinicians to enhance patient care."
In addition, this year's ASA meeting includes three educational panel sessions related to cerebral protection emphasizing increasing awareness of the need for additional measures to enhance cerebral outcomes and highlighting the role that non-invasive cerebral oximetry monitoring can play in brain protection.
The presentations are as follows:
-
The Effect of Phenylephrine Administration on Maternal Cerebral Tissue Oxygenation Following Spinal Anesthesia for Cesarean Delivery, T. Allen, et al, Duke University Medical Center, Durham, N.C. A 14 patient study compared cerebral saturation levels arising from differing methods of drug delivery that are often used to manage blood pressure in women during cesarean delivery and spinal anesthesia.
-
Intraoperative Cerebral Tissue Oxygenation and Postoperative Cognitive Dysfunction After On- and Off-Pump Coronary Artery Bypass Surgery, A. Absalom, et al, University Medical Centre Groningen, Groningen, the Netherlands. This presentation of a 59 patient study showed a very high incidence of post-operative cognitive dysfunction in both on-pump (39%) and off-pump CABG surgery (45%.)
-
Effect of Atropine, Norepinephrine and Phenylephrine on Cerebral Oxygenation and Cardiac Output During Anesthesia, A. Kalmar, et al, University Medical Centre Groningen, Groningen, the Netherlands. This study of 60 patients undergoing ophthalmic surgery utilized cerebral monitoring to help determine which drug regimen resulted in optimized organ perfusion.
-
Cerebral Desaturation Events During Shoulder Surgery in the Beach Chair Position: General Versus Regional Anesthesia, G Murphy, et al, NorthShore University HealthSystem, Evanston, Ill. This study of 60 patients showed a significant incidence (56%) of cerebral desaturations in patients with general anesthesia requiring significant interventions compared to a lack of desaturations in patients with local anesthesia.
- The Geriatric Surgical Patient: Stress, Anesthetics, and Functional Outcomes, S. Deiner, et al, The Mount Sinai School of Medicine, New York, N.Y., United States. This presentation noted that among other findings in a study of 30 geriatric patients during general surgery, cerebral desaturations showed a trend toward association with post-operative delirium.
About CASMED® – Monitoring What's Vital
CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care.
For further information regarding CASMED, visit the Company's website at www.casmed.com.
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2011 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.